Generation, Characterization, and Validation of Marmoset Models of Alzheimer's Disease

总体项目总结 阿尔茨海默病是一种毁灭性的神经退行性疾病，影响着近600万美国人和 预计在未来几年内将会增加。我们对触发机制的有限理解 阿尔茨海默病的出现导致缺乏阻止、预防或完全治疗这种疾病的干预措施。 我们建议建立绒猴作为第一个灵长类特有的模型，以揭示最早的细胞和 AD过程的分子事件并允许从一开始就绘制AD进程的图表。为此，我们将抽签 从一个自给自足、拥有专门兽医和畜牧团队的研究绒猴群体， 最先进的活体神经成像和分子分析，以及一个多学科的衰老专家团队 生物学、阿尔茨海默病遗传学和基因组学、动物模型开发和表征、行为和认知 表型和绒猴基因编辑技术。我们提案的首要目标是开发 早发性AD(EoAD)和晚发性AD(LOAD)的绒猴模型 阿尔茨海默病发病和进展的潜在细胞和分子根本原因并支持未来 翻译研究。我们认为，对遗传、分子、功能、行为、 而绒猴的病理表型将提供有关糖尿病起源和发展的可翻译知识。 人类人群中的AD。此外，我们假设，对基因编辑的绒猴模型的综合研究 从神经发育到衰老的阿尔茨海默病的研究将确定弗兰克之前的新表型 神经病理学。我们的建议由3个综合研究项目组成，旨在：(1)进行 作为研究EoAD模型的绒猴PSEN1突变的特征和验证，以及 研究阿尔茨海默病发病机制的早期生命分子决定因素与EoAD的遗传风险； (2)识别和加强近交系和基因工程绒猴的负荷相关特征；及(3) 对AD的绒猴模型进行比较的多模式表型表征。这些项目将 由5个研究核心支持，重点是项目管理、生物信息学、遗传工程、 多模式疾病特征，以及兽医和群体管理。这些支持核心将 整合绒猴和人类基因组签名，并向更大的 作为我们致力于开放科学，产生新的基因编辑绒猴模型的一部分，研究社区 为研究AD的发病和轨迹制定符合临床方案的优化方案， 评估治疗策略，并分别提供专门的动物护理和支持，允许 毛猴模型的完整表征。在这个项目结束时，我们将从基因上 将三种AD风险变种改造成绒猴模型，建立了疾病特征描述管道 全面的表型分析，并与更大的研究社区分享这些资源。

PROJECT SUMMARY OVERALL Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting nearly 6 million Americans and is expected to increase over the next several years. Our limited understanding of the mechanisms that trigger the emergence of AD has contributed to the lack of interventions that stop, prevent, or fully treat this disease. We propose to establish the marmoset as the first primate-specific model to reveal the earliest cellular and molecular events of AD processes and allow charting AD progression from its inception. To do so, we will draw from a self-sufficient and large colony of research marmosets with dedicated veterinary and husbandry teams, state-of-the-art in vivo neuroimaging and molecular assays, and a multidisciplinary team of experts in aging biology, AD genetics and genomics, animal model development and characterization, behavioral and cognitive phenotyping, and marmoset gene-editing technologies. Our proposal’s overarching goals are to develop marmoset models of early-onset AD (EOAD) and late-onset AD (LOAD) to enable the investigation of the underlying cellular and molecular root causes of the pathogenesis and progression of AD and support future translational studies. We believe that the simultaneous assessment of genetic, molecular, functional, behavioral, and pathological phenotypes in marmosets will provide translatable knowledge of the origins and progression of AD in human populations. Furthermore, we posit that the comprehensive study of gene-edited marmoset models of AD from neurodevelopment through aging will identify emerging phenotypes that precede frank neuropathology. Our proposal consists of 3 integrated Research Projects that aim to: (1) Conduct characterization and validation of PSEN1 mutations in marmosets as a model for the study of EOAD, and investigate early life molecular determinants of AD disease pathogenesis associated with genetic risk for EOAD; (2) Identify and enhance LOAD-related signatures in outbred and genetically-engineered marmosets; and (3) Conduct a comparative multimodal phenotypic characterization of marmoset models of AD. These projects will be supported by 5 Research Cores focused on project administration, bioinformatics, genetic engineering, multimodal disease characterization, and veterinary and colony management. These supporting cores will integrate marmoset and human genomic signatures and provide data dissemination and resources to the greater research community as part of our commitment to open science, generate novel gene-edited marmoset models of AD, develop optimized protocols for studying disease onset and trajectory in line with clinical protocols, evaluate therapeutic strategies, and provide specialized animal care and support, respectively, allowing complete characterization of the marmoset models. At the conclusion of this project, we will have genetically engineered three AD risk variants into marmoset models, established a disease characterization pipeline for comprehensive phenotyping, and shared these resources with the greater research community.